Lucie Raskin

Lucie Raskin is an active researcher affiliated with Henallux and the Centre Namur Simulation. Her work focuses on pharmacology, endocrinology, and medical research, particularly the comparative risks of natural and synthetic estrogens in combined oral contraceptives (COCs) related to venous thromboembolism (VTE).

Research Interests: Raskin's research explores the safety profiles of hormonal contraceptives, with a focus on natural estrogens versus ethinylestradiol in reducing VTE risks. She employs methods like systematic literature reviews, meta-analyses, and disproportionality analysis of large databases such as the Eudravigilance Database.

Recent Publications: In 2024, she co-authored two peer-reviewed articles on COC safety. One article in Contraception demonstrated reduced VTE risks with natural estrogen-based COCs, while another in Frontiers in Endocrinology systematically reviewed this comparative risk profile.

Academic Activities: Raskin participated in the European Society of Gynecology 2025 conference in Riga and presented her work at the Centre Namur Simulation - Henallux workshop from October 2024 to October 2025.